Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. Nov 5, 2024; 15(6): 99097
Published online Nov 5, 2024. doi: 10.4292/wjgpt.v15.i6.99097
Published online Nov 5, 2024. doi: 10.4292/wjgpt.v15.i6.99097
Table 1 Classification systems for endoscopic and computed tomography grading of acute corrosive injuries
| Modified Zargar endoscopic grading[1] | |
| Grade 0 | Normal |
| Grade I | Oedema and hyperaemia of mucosa |
| Grade IIA | Superficial localised ulcerations, friability and blisters |
| Grade IIB | Circumferential and deep ulcerations |
| Grade IIIA | Multiple and deep ulcerations and small, scattered areas of necrosis |
| Grade IIIB | Extensive necrosis |
| Grade IV | Perforation |
| CT grading[2] | |
| Grade 1 | Normal appearance |
| Grade 2 | Wall and soft tissue oedema, increased wall enhancement |
| Grade 3 | Transmural necrosis with absent wall enhancement (with or without perforation) |
Table 2 Baseline demographics and details of the corrosive ingestion incident
| Baseline demographics (n = 100) | n | % |
| Gender | ||
| Female | 35 | 35.0 |
| Male | 65 | 65.0 |
| Comorbidities | ||
| No | 67 | 67.0 |
| Yes | 33 | 33.0 |
| Specified comorbidities | ||
| Known psychiatric history | 15 | 15.0 |
| HIV positive | 12 | 12.0 |
| Hypertension | 2 | 2.0 |
| Obesity | 3 | 3.0 |
| Diabetes mellitus | 1 | 1.0 |
| Other comorbidity | 7 | 7.0 |
| Substance use | ||
| No | 59 | 59.0 |
| Yes | 41 | 41.0 |
| Substance use specified | ||
| Smoking | 31 | 31.0 |
| Alcohol - regular use | 21 | 21.0 |
| Marijuana | 10 | 10.0 |
| Methamphetamine | 8 | 8.0 |
| Methaqualone | 7 | 7.0 |
| Opioids | 1 | 1.0 |
| Prior corrosive ingestion/suicide attempt | ||
| Yes | 11 | 11.0 |
| No | 89 | 89.0 |
| Corrosive ingestion incident (n = 100) | ||
| Intentional/accidental | ||
| Intentional (suicidal) | 73 | 73.0 |
| Accidental | 20 | 20.0 |
| Forced ingestion (assault) | 5 | 5.0 |
| Unknown | 2 | 2.0 |
| Substance ingested | ||
| Acid | 32 | 32.0 |
| Sulphuric acid | 22 | |
| Hydrochloric acid | 3 | |
| Other acid | 7 | |
| Alkali | 58 | 58.0 |
| Sodium hypochlorite (bleach) | 30 | |
| Sodium hydroxide | 27 | |
| Other alkali | 3 | |
| Other corrosive substance | 10 | 10.0 |
| Unknown corrosive substance | 5 | 5.0 |
Table 3 Imaging and endoscopy investigations performed on admission
| Imaging/endoscopy during acute admission (n = 100) | n | % | n | % | n | % |
| Endoscopy | 95 | 95.0 | ||||
| Chest X-ray | 82 | 82.0 | ||||
| Lateral neck X-ray | 31 | 31.0 | ||||
| CT | 17 | 17.0 | ||||
| Contrast swallow | 1 | 1.0 | ||||
| None | 1 | 1.0 | ||||
| Endoscopy findings (n = 95) | n | % | n | % | n | % |
| Oesophagus | Stomach | Duodenum | ||||
| Not entered | 1 | 1.1 | 3 | 3.2 | 32 | 33.7 |
| Zargar 0 | 23 | 24.2 | 14 | 14.7 | 42 | 44.2 |
| Zargar I | 11 | 11.6 | 25 | 26.3 | 9 | 9.5 |
| Zargar IIA | 20 | 21.1 | 14 | 14.7 | 7 | 7.4 |
| Zargar IIB | 26 | 27.4 | 8 | 8.4 | 1 | 1.1 |
| Zargar IIIA | 6 | 6.3 | 16 | 16.8 | 1 | 1.1 |
| Zargar IIIB | 8 | 8.4 | 14 | 14.7 | 3 | 3.2 |
| Zargar IV | 0 | 0.0 | 1 | 1.1 | 0 | 0.0 |
| CT findings (n = 17) | n | % | n | % | ||
| Oesophagus | Stomach | |||||
| Grade 1 - normal | 2 | 11.8 | 5 | 29.4 | ||
| Grade 2 - oedematous only | 11 | 64.7 | 8 | 47.1 | ||
| Grade 3 - lack of contrast enhancement | ||||||
| Without perforation | 3 | 17.6 | 2 | 11.8 | ||
| With perforation | 1 | 5.9 | 2 | 11.8 | ||
Table 4 Overview of acute management
| Management | ||
| Median (IQR) time from ingestion to first healthcare assessment | 6 (2-13) hours | |
| Emergency resuscitation | n | % |
| Required emergency resuscitation | 23 | 23.0 |
| Specified | ||
| Endotracheal intubation | 19 | 19.0 |
| Chest compressions | 1 | 1.0 |
| Inotropes | 3 | 3.0 |
| Other1 | 2 | 2.0 |
| Other management initiated in the emergency department | ||
| Proton pump inhibitor therapy | 35 | 35.0 |
| Prophylactic antibiotics | 7 | 7.0 |
| Therapeutic antibiotics | 4 | 4.0 |
| Nasogastric tube insertion (for drainage, not feeding) | 4 | 4.0 |
| Activated charcoal administration | 4 | 4.0 |
| Steroids | 1 | 1.0 |
| Neutralizing agent | 0 | 0.0 |
| Surgery | ||
| Required acute surgery | 20 | 20.0 |
| Decision for needing surgery (n = 20) | ||
| Based on endoscopy findings | 13 | 65.0 |
| Based on CT findings | 5 | 25.0 |
| Based on clinical findings only | 2 | 10.0 |
| Type of surgery (n = 20) | ||
| Emergency resection performed | 11 | 55.0 |
| Oesophagectomy only | 1 | |
| Oesophagogastrectomy | 5 | |
| Gastrectomy only | 5 | |
| Extended resections2 | 2 | |
| Exploration only - decision for palliation | 6 | 30.0 |
| Feeding jejunostomy (only) | 1 | 5.0 |
| Gastrojejunostomy & gastrostomy | 1 | 5.0 |
| Negative laparotomy | 1 | 5.0 |
Table 5 Outcomes for 30-days post corrosive ingestion. Acute admission outcomes
| Outcomes (n = 100) | n | % |
| 30-day mortality | 14 | 14.0 |
| 30-day morbidity | 27 | 27.0 |
| Required ICU management | 26 | 26.0 |
| Median (IQR) ICU stay | 2.5 (2-3.25) days | |
| Median (IQR) length of hospital stay | 6 (2-15.5) days | |
| Acute morbidities specified (n = 39) | ||
| Pneumonia (nosocomial) | 7 | 17.9 |
| Acute kidney injury | 5 | 12.8 |
| Cardiac arrest (unexpected) | 4 | 10.3 |
| Refeeding syndrome | 3 | 7.7 |
| Systemic sepsis | 2 | 5.1 |
| Unplanned extubation | 2 | 5.1 |
| Surgical site infection | 2 | 5.1 |
| Other | 14 | 35.9 |
Table 6 Multivariate analysis of numerous admission variables in predicting full thickness necrosis and short-term mortality, n (%)
| Variables | Predicting full thickness necrosis | Predicting acute mortality | ||||||||||||
| Total, n | No FT necrosis | FT necrosis | P value | ROC AUC | No mortality | Mortality | P value | ROC AUC | ||||||
| Gender | Female | 35 | 31 | 88.6 | 4 | 11.4 | 0.279 | 28 | 80.0 | 7 | 20.0 | 0.207 | ||
| Male | 65 | 52 | 80 | 13 | 20 | 58 | 89.2 | 7 | 10.8 | |||||
| At least one comorbidity | No | 67 | 58 | 86.6 | 9 | 13.4 | 0.178 | 56 | 83.6 | 11 | 16.4 | 0.323 | ||
| Yes | 33 | 25 | 75.8 | 8 | 24.2 | 30 | 90.9 | 3 | 9.1 | |||||
| Known psychiatric history | No | 85 | 71 | 83.5 | 14 | 16.5 | 0.739 | 72 | 84.7 | 13 | 15.3 | 0.377 | ||
| Yes | 15 | 12 | 80 | 3 | 20 | 14 | 93.3 | 1 | 6.7 | |||||
| Known HIV positive | No | 88 | 75 | 85.2 | 13 | 14.8 | 0.11 | 74 | 84.1 | 14 | 15.9 | 0.138 | ||
| Yes | 12 | 8 | 66.7 | 4 | 33.3 | 12 | 100.0 | 0 | 0.0 | |||||
| Prior corrosive/suicide attempt | No | 89 | 75 | 84.3 | 14 | 15.7 | 0.339 | 77 | 86.5 | 12 | 13.5 | 0.673 | ||
| Yes | 11 | 8 | 72.7 | 3 | 27.3 | 9 | 81.8 | 2 | 18.2 | |||||
| Needing endotracheal intubation | No | 82 | 71 | 86.6 | 11 | 13.4 | 0.043 | 0.604 | 69 | 84.1 | 13 | 15.9 | 0.257 | |
| Yes | 18 | 12 | 66.7 | 6 | 33.3 | 17 | 94.4 | 1 | 5.6 | |||||
| Needing chest compressions | No | 99 | 83 | 83.8 | 16 | 16.2 | 0.027 | 0.529 | 85 | 85.9 | 14 | 14.1 | 0.687 | |
| Yes | 1 | 0 | 0 | 1 | 100 | 1 | 100.0 | 0 | 0.0 | |||||
| Needing inotropes/vasopressors | No | 97 | 81 | 83.5 | 16 | 16.5 | 0.447 | 83 | 85.6 | 14 | 14.4 | 0.480 | ||
| Yes | 3 | 2 | 66.7 | 1 | 33.3 | 3 | 100.0 | 0 | 0.0 | |||||
| ≥ Zargar IIIB endoscopic findings | No | 79 | 75 | 94.9 | 4 | 5.1 | < 0.001 | 0.85 | 74 | 93.7 | 5 | 6.3 | < 0.001 | 0.759 |
| Yes | 16 | 4 | 25 | 12 | 75 | 8 | 50.0 | 8 | 50.0 | |||||
| Grade 3 CT Findings | No | 12 | 10 | 83.3 | 2 | 16.7 | 0.016 | 0.788 | 11 | 91.7 | 1 | 8.3 | 0.026 | 0.798 |
| Yes | 5 | 1 | 20 | 4 | 80 | 2 | 40.0 | 3 | 60.0 | |||||
| Age (years) | 100 | 31 (24-38) | 39 (30-50) | 0.015 | 0.687 | 32 (24-40) | 31 (25-40) | 0.917 | ||||||
| Systolic BP (mmHg) | 48 | 134 (114-143) | 129 (113-149) | 0.926 | 130 (113-144) | 134 (120-137) | 0.919 | |||||||
| Diastolic BP (mmHg) | 48 | 80 (73-90) | 83 (75-97) | 0.309 | 82 (73-90) | 79 (64-91) | 0.520 | |||||||
| Heart rate (beats per minute) | 48 | 94 (79-109) | 86 (72-105) | 0.405 | 93 (76-110) | 94 (82-107) | 0.965 | |||||||
| Urea (mmol/L) | 79 | 4.6 (3.3-5.9) | 5.1 (2.7-7.1) | 0.686 | 4.7 (3.2-6.5) | 3.9 (3.4-5.4) | 0.432 | |||||||
| Creatinine (umol/L) | 88 | 70 (57-81) | 84 (68-102) | 0.038 | 0.666 | 72 (58-85) | 72 (66-84) | 0.892 | ||||||
| WCC (× 109/L) | 85 | 14.07 (9.58-18.31) | 13.80 (9.76-19.16) | 0.695 | 13.79 (9.59-18.31) | 15.75 (10.63-20.50) | 0.605 | |||||||
| Platelets (× 109/L) | 81 | 253 (210-326) | 206 (171-266) | 0.045 | 0.666 | 245 (194-308) | 263 (232-375) | 0.142 | ||||||
| Calcium (mmol/L) | 12 | 2.21 (2.00-2.35) | 1.99 (199-1.99) | 0.31 | 2.15 (1.99-2.35) | 2.21 (2.21-2.21) | 0.885 | |||||||
| pH | 41 | 7.37 (7.31-7.42) | 7.13 (7.07-7.35) | 0.003 | 0.823 | 7.35 (7.17-7.40) | 7.36 (7.27-7.43) | 0.593 | ||||||
| Base excess (mEq/L) | 40 | -0.50 (-5.50-2.10) | -14.20 (-17.00 to -4.60) | 0.004 | 0.819 | -3.2 (-12.1-0.65) | 2.45 (-0.58-5.38) | 0.020 | 0.199 | |||||
| Lactate (mmol/L) | 40 | 1.80 (1.20-3.30) | 3.20 (2.60-4.45) | 0.026 | 0.746 | 2.45 (1.20-3.55) | 1.55 (1.18-3.48) | 0.677 | ||||||
| Ingestion to first assessment (hours) | 94 | 6.0 (2.5-14.5) | 4.0 (2.0-8.5) | 0.209 | 6.0 (3.0-15.5) | 3.0 (1.5-6.5) | 0.052 | |||||||
Table 7 Admission endoscopy, computed tomography and blood gas performance in predicting full thickness necrosis
| Total | FT necrosis | Not FT necrosis | Sensitivity, % | Specificity, % | PPV, % | NPV, % | P value | ROC AUC | |
| Endoscopy performance (n = 95) | |||||||||
| Zargar IIIB | 16 | 12 | 4 | 75.0 | 94.9 | 75.0 | 94.5 | < 0.001 | 0.850 |
| CT performance (n = 17) | |||||||||
| CT grade 3 | 5 | 4 | 1 | 66.7 | 90.9 | 80.0 | 83.3 | 0.026 | 0.788 |
| Blood gas performance (n = 40) | |||||||||
| pH < 7.35 | 20 | 7 | 13 | 77.8 | 58.1 | 35.0 | 90.0 | 0.062 | 0.679 |
| BE < -2 mEq/L | 18 | 7 | 11 | 77.8 | 64.5 | 38.9 | 90.9 | 0.027 | 0.711 |
| Lactate > 2.0 mmol/L | 21 | 8 | 13 | 88.9 | 58.1 | 38.1 | 94.7 | 0.014 | 0.735 |
| Blood gas performance (Patients with concomitant toxin ingestion removed) (n = 35) | |||||||||
| pH < 7.35 | 19 | 7 | 12 | 77.8 | 58.1 | 35.0 | 100.0 | 0.007 | 0.786 |
| BE < -2 mEq/L | 17 | 7 | 10 | 77.8 | 58.1 | 35.0 | 100.0 | 0.003 | 0.821 |
| Lactate > 2.0 mmol/L | 18 | 6 | 12 | 77.8 | 58.1 | 35.0 | 94.1 | 0.046 | 0.714 |
- Citation: Scriba MF, Jonas E, Chinnery GE. Predicting full-thickness necrosis in adult acute corrosive ingestion injuries in a sub-Saharan African setting. World J Gastrointest Pharmacol Ther 2024; 15(6): 99097
- URL: https://www.wjgnet.com/2150-5349/full/v15/i6/99097.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i6.99097
